Intracellular Therapeutics Pipeline
Diverse and Expanding Pipeline of RNA-, Antibody- and Enzyme-Based Programs Spanning Discovery and Clinical Development
At Entrada Therapeutics, we are driven to transform the lives of patients by establishing a new class of intracellular therapeutics. We are already developing potential treatments across multiple devastating diseases with a simple and scalable EEV platform designed to translate from preclinical to clinical development.
Duchenne Muscular Dystrophy (DMD)
ENTR-601-44 (Exon 44 Skipping Oligonucleotide)
ENTR-601-45 (Exon 45 Skipping Oligonucleotide)
ENTR-601-50 (Exon 50 Skipping Oligonucleotide)
Exon 51 (Exon 51 Skipping Oligonucleotide)
Myotonic Dystrophy Type 1 (DM1)
VX-670 (Oligonucleotide) 1
Pipeline Expansion
Undisclosed Ocular
Undisclosed Programs
Platform Expansion
-
1.
In collaboration with